Press Release
news head

July 31, 2018

Cancer Screening Company Nucleix Raises 2.5 Million Euros

read more >

Press Release
news head

July 30, 2018

Israeli cancer detection co Nucleix wins €2.5m EU grant

read more >

Press Release
news head

July 26, 2018

Cancer Diagnostics Firm Nucleix Plans European Market Expansion

read more >

Press Release
news head

July 26, 2018

European study green-lights Israeli test for recurrence of bladder cancer

read more >

Press Release
news head

July 24, 2018

Nucleix Announces Publication of Non-Invasive Bladder Cancer Recurrence Detection Study Showing Best-in-Class Performance

read more >

Article
news head

July 1, 2018

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial

read more >

Article
news head

April 12, 2018

Bladder EpiCheck Multi-Center Study Results Were Presented During the European Association of Urology (EAU) Annual Meeting

Clinical results of multi-center study with five leading urology centers were accepted as a poster and presented during the EAU meeting in Copenhagen, Denmark. The EAU meeting is the largest urology meeting in Europe and 2nd largest in the world.

read more >

Press Release
news head

April 5, 2018

Leading European Bladder Cancer Experts: The Bladder EpiCheck Urine Test Can Reduce Invasive Procedures

read more >

Article
news head

November 20, 2017

Nucleix Exhibited Bladder EpiCheck at the Annual Meeting of the European Multidisciplinary Meeting on Urological Cancers (EMUC)

Nucleix exhibited Bladder EpiCheck, best-in-class bladder cancer monitoring test, during the European Multidisciplinary Meeting on Urological Cancers (EMUC). The EMUC meeting one of Europe’s well-attended international conferences for multidisciplinary specialists with expertise in urological malignancies. During the meeting, Nucleix met

read more >

Article
news head

October 23, 2017

Nucleix Exhibited Bladder EpiCheck at the Annual Meeting of the Société Internationale d’Urologie (SIU) in Lisbon

Nucleix exhibited Bladder EpiCheck, best-in-class bladder cancer monitoring test, during the annual meeting of the Société Internationale d’Urologie (SIU). The SIU meeting is the world’s 3rd largest urology meeting that took place in Lisbon and included over 2,000 participants from

read more >